Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Director Amy Mcbride Wendell purchased 16,264 shares of Ekso Bionics Holdings stock in a transaction on Thursday, September 14th. The shares were purchased at an average cost of $1.23 per share, with a total value of $20,004.72. Following the transaction, the director now owns 16,264 shares in the company, valued at $20,004.72. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) traded down 6.50% during midday trading on Friday, hitting $1.15. The stock had a trading volume of 613,937 shares. Ekso Bionics Holdings, Inc. has a 1-year low of $0.99 and a 1-year high of $6.38. The stock’s market capitalization is $29.66 million. The stock’s 50-day moving average is $1.47 and its 200-day moving average is $2.19.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/ekso-bionics-holdings-inc-ekso-director-amy-mcbride-wendell-buys-16264-shares-of-stock.html.

Separately, Zacks Investment Research downgraded Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EKSO. Carl Domino Inc increased its holdings in shares of Ekso Bionics Holdings by 74.7% during the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after acquiring an additional 35,088 shares in the last quarter. Intellectus Partners LLC boosted its position in shares of Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares during the last quarter. National Planning Corp boosted its position in shares of Ekso Bionics Holdings by 116.2% during the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the last quarter. Finally, Independence Advisors LLC purchased a new position in shares of Ekso Bionics Holdings during the second quarter valued at approximately $1,840,000. Hedge funds and other institutional investors own 6.04% of the company’s stock.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.